Actinium Pharmaceuticals Updates Status Of Bone-Blood Cancer Treatments

Actinium Pharmaceuticals Updates Status Of Bone-Blood Cancer Treatments

Actinium Pharmaceuticals Thursday said it would host a webinar on its drug Actimab-A for the treatment of acute myeloid leukemia (AML), a type of bone-blood cancer, on July 13. Actinium said, “Until this year, Mylotarg, which targets CD33, was the only drug approved for the treatment of AML in several decades. The drug was withdrawn from the market and the sponsor (Pfizer, PFE) recently resubmitted a BLA (biologics license application) […]

Read More ˃